Hereditary angioedema: Long-term prophylactic treatment

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Hereditary Angioedema (HAE) is a rare, potentially fatal genetic disorder characterized by unpredictable swelling episodes.
• HAE significantly impacts patients' quality of life, necessitating effective disease management strategies.
• The primary goals in HAE management are to reduce morbidity and mortality through timely interventions.

Purpose of the Study:

• To review the evolving landscape of long-term prophylaxis (LTP) options for Hereditary Angioedema.
• To highlight the shift towards more targeted therapies in HAE management.
• To discuss current and emerging therapeutic strategies for HAE attack prevention.

Main Methods:

• Review of current literature on Hereditary Angioedema treatments.
• Analysis of established and novel therapeutic agents for HAE long-term prophylaxis.
• Discussion of clinical investigations into new HAE treatment modalities.

Main Results:

• Current HAE long-term prophylaxis primarily utilizes C1 INH concentrate and plasma kallikrein inhibitors (intravenous or subcutaneous).
• These newer agents have largely superseded older treatments such as androgen derivatives and antifibrinolytics.
• Emerging therapies including oral kallikrein inhibitors, antisense RNA, anti-Factor 12a, bradykinin receptor blockers, and gene therapy are under investigation.

Conclusions:

• The availability of diverse HAE long-term prophylaxis options allows for individualized patient treatment.
• Cost and long-term safety data remain key considerations for the clinical application of new HAE therapies.
• Limited data in specific populations (young children, pregnant women) presents challenges in risk-benefit assessments for HAE prophylaxis.